Interindividual variability in hepatic drug glucuronidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system

Drug Metabolism Reviews

Volumn 42, Issue 1, 2010, Pages 209-224

  Court, Michael H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Glucuronidation; Liver; Pharmacogenetics; Sex; Variability

Indexed keywords

ADRENALIN; ATROPINE; CEFAZOLIN; CEFOTAXIME; DESMOPRESSIN; DEXAMETHASONE; DOPAMINE; ERYTHROMYCIN; FUROSEMIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A5; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2A3; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B28; GLUCURONOSYLTRANSFERASE 2B7; HYDROCORTISONE; INSULIN; LABETALOL; METOPROLOL; MORPHINE; NAFCILLIN; NORADRENALIN; PENICILLIN G; RANITIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGE; AGED; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME POLYMORPHISM; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LIVER METABOLISM; MALE; ORGAN DONOR; PHARMACOGENETICS; PRESCHOOL CHILD; REVIEW; SCHOOL CHILD; SEX DIFFERENCE;

EID: 74549132748     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602530903209288     Document Type: Review

References (94)

1. Argikar, U. A., Remmel, R. P. (2009). Efect of aging on glucuronida-tion of valproic acid in human liver microsomes and the role of UDP- glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 37:229-236.
2. Basu, N. K., Kole, L., Owens, I. S. (2003). Evidence for phos-phorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity. Biochem Biophys Res Commun 303:98-104.
3. Belanger, A. S., Caron, P., Harvey, M., Zimmerman, P. A., Mehlotra, R. K., Guillemette, C. (2009). Glucuronidation of the antiretroviral drug efavirenz (EFV) by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine (AZT). Drug Metab Dispos Epub Jun 1.
4. Bock, K. W., Schrenk, D., Forster, A., Griese, E. U., Morike, K., Brockmeier, D., et al. (1994). Te infuence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, cafeine, and paracetamol as probes. Pharmacogenetics 4:209-218.
5. Bock, K. W., Wiltfang, J., Blume, R., Ullrich, D., Bircher, J. (1987). Paracetamol as a test drug to determine glucuronide formation in man. Efects of inducers and of smoking. Eur J Clin Pharmacol 31:677-683.
6. Burchell, B., Coughtrie, M., Jackson, M., Harding, D., Fournel-Gigleux, S., Leakey, J., et al. (1989). Development of human liver UDP- glucuronosyltransferases. Dev Pharmacol Ter 13(2-4):70-77.
7. Chen, G., Blevins-Primeau, A. S., Dellinger, R. W., Muscat, J. E., Lazarus, P. (2007a). Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Res 67:9024-9029.
8. Chen, G., Dellinger, R. W., Gallagher, C. J., Sun, D., Lazarus, P. (2008). Identifcation of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specifc nitrosamines. Pharmacogenet Genomics 18(3):181-191.
9. Chen, Y., Kuehl, G. E., Bigler, J., Rimorin, C. F., Schwarz, Y., Shen, D. D., et al. (2007b). UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenet Genom 17:571-579.
10. Choonara, I. A., McKay, P., Hain, R., Rane, A. (1989). Morphine metabolism in children. Br J Clin Pharmacol 28:599-604.
11. Ciotti, M., Marrone, A., Potter, C., Owens, I. S. (1997). Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7:485-495.
12. Congiu, M., Mashford, M. L., Slavin, J. L., Desmond, P. V. (2002). UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
13. Coughtrie, M. W., Burchell, B., Leakey, J. E., Hume, R. (1988). Te inadequacy of perinatal glucuronidation: immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol Pharmacol 34:729-735.
14. Court, M. H. (2004). In vitro identifcation of UDP- glucuronosyltransferases (UGTs) involved in drug metabolism. In: Yan, Z., Caldwell, G. W. (Eds.), Optimization in drug discovery: in vitro methods (pp. 185-202). Totowa: Humana Press.
15. Court, M. H. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Meth Enzymol 400:104-116.
16. Court, M. H., Duan, S. X., Guillemette, C., Journault, K., Krishnaswamy, S., von Moltke, L. L., et al. (2002). Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 30:1257-1265.
17. Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., et al. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identifca-tion of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ter 299:998-1006.
18. Court, M. H., Hao, Q., Krishnaswamy, S., Bekaii-Saab, T., Al-Rohaimi, A., Von Moltke, L. L., et al. (2004). UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ter 310:656-665.
19. Court, M. H., Hazarika, S., Krishnaswamy, S., Finel, M., Williams, J. A. (2008). Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol Pharmacol 74:744-754.
20. Court, M. H., Krishnaswamy, S., Hao, Q., Duan, S. X., Patten, C. J., von Moltke, L. L., et al. (2003). Evaluation of 3'-azido-3'-de-oxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specifcity and infuence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
21. Court, M. H., von Moltke, L. L., Shader, R. I., Greenblatt, D. J. (1997). Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 18:213-226.
22. de Wildt, S. N., Kearns, G. L., Leeder, J. S., van den Anker, J. N. (1999). Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36:439-452.
23. Dragacci, S., Hamar-Hansen, C., Fournel-Gigleux, S., Lafaurie, C., Magdalou, J., Siest, G. (1987). Comparative study of clofbric acid and bilirubin glucuronidation in human liver microsomes. Biochem Pharmacol 36:3923-3927.
24. Duguay, Y., Baar, C., Skorpen, F., Guillemette, C. (2004). A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with signifcant impact on promoter activity. Clin Pharmacol Ter 75:223-233.
25. Ehmer, U., Vogel, A., Schutte, J. K., Krone, B., Manns, M. P., Strassburg, C. P. (2004). Variation of hepatic glucuro-nidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39:970-977.
26. Ernstgard, L., Johanson, G., Karlsson, A. S., Warholm, M. (2007). Phenotyping of cytochrome P450 2E1 in vitro and in vivo. Curr Drug Metab 8:493-498.
27. Fleischmann, R., Remmer, H., Starz, U. (1986). Induction of cyto-chrome P-448 iso-enzymes and related glucuronyltransferases in the human liver by cigarette smoking. Eur J Clin Pharmacol 30:475-480.
28. Girard, H., Court, M. H., Bernard, O., Fortier, L. C., Villeneuve, L., Hao, Q., et al. (2004). Identifcation of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501-515.
29. Girard, H., Tibaudeau, J., Court, M. H., Fortier, L. C., Villeneuve, L., Caron, P., et al. (2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxifcation in the liver. Hepatology 42:448-457.
30. Girard, H., Villeneuve, L., Court, M. H., Fortier, L. C., Caron, P., Hao, Q., et al. (2006). Te novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glu-curonidation levels in the liver. Drug Metab Dispos 34:1220-1228.
31. Girre, C., Hispard, E., Palombo, S., N'Guyen, C., Dally, S. (1993). Increased metabolism of acetaminophen in chronically alcoholic patients. Alcohol Clin Exp Res 17:170-173.
32. Greenblatt, D. J., Divoll, M., Harmatz, J. S., Shader, R. I. (1980). Oxazepam kinetics: efects of age and sex. J Pharmacol Exp Ter 215:86-91.
33. Greenblatt, D. J., Harmatz, J. S., Shader, R. I. (1991). Clinical pharma-cokinetics of anxiolytics and hypnotics in the elderly. Terapeutic considerations (Part I). Clin Pharmacokinet 21:165-177.
34. Greenblatt, D. J., von Moltke, L. L. (2008). Gender has a small but statistically signifcant efect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48:1350-1355.
35. He, P., Court, M. H., Greenblatt, D. J., Von Moltke, L. L. (2005). Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ter 77:373-387.
36. Hesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., von Moltke, L. L., et al. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cyto-chrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238.
37. Hines, R. N. (2008). Te ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ter 118:250-267.
38. Holthe, M., Rakvag, T. N., Klepstad, P., Idle, J. R., Kaasa, S., Krokan, H. E., et al. (2003). Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identifcation of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenom J 3:17-26.
39. Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., et al. (2003). Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A 100:4156-4161.
40. Innocenti, F., Liu, W., Fackenthal, D., Ramirez, J., Chen, P., Ye, X., et al. (2008). Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genom 18:683-697.
41. Kardon, T., Cofey, M. J., Banhegyi, G., Conley, A. A., Burchell, B., Mandl, J., et al. (2000). Transcriptional induction of bilirubin UDP-glucuronosyltransrase by ethanol in rat liver. Alcohol 21:251-257.
42. Kardon, T., Mile, V., Banhegyi, G., Csala, M., Burchell, B., Mandl, J., et al. (2002). Ethanol-dependent induction of bilirubin UDP-glucuronosyl- transferase in rat liver is mediated by Kupfer cells. Life Sci 70:1205-1212.
43. Klotz, U. (2009). Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67-76.
44. Krishnaswamy, S., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Court, M. H. (2003a). Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133-139.
45. Krishnaswamy, S., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Sudmeier, J. L., Bachovchin, W. W., et al. (2003b). Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities, and species difer-ences. Xenobiotica 33:169-180.
46. Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., von Moltke, L. L., Greenblatt, D. J., et al. (2005a). UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identifcation of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronida-tion. J Pharmacol Exp Ter 313:1331-1339.
47. Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., von Moltke, L. L., Greenblatt, D. J., et al. (2005b). UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ter 313:1340-1346.
48. Krishnaswamy, S., Hao, Q., von Moltke, L. L., Greenblatt, D. J., Court, M. H. (2004). Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1a6. Drug Metab Dispos 32:862-869.
49. Kwara, A., Lartey, M., Boamah, I., Rezk, N. L., Oliver-Commey, J., Keny, E., et al. (2009). Interindividual variability in pharmacoki-netics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients. UGT2B7*1C is associated with faster zidovadine clearance and glucuronidation. J Clin Pharmacol 49(9):1079-1090.
50. Lazarus, P., Zheng, Y., Aaron Runkle, E., Muscat, J. E., Wiener, D. (2005). Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genom 15:769-778.
51. Leakey, J. E., Hume, R., Burchell, B. (1987). Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem J 243:859-861.
52. Levesque, E., Benoit-Biancamano, M. O., Delage, R., Couture, F., Guillemette, C. (2008). Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 9:869-879.
53. Levesque, E., Delage, R., Benoit-Biancamano, M. O., Caron, P., Bernard, O., Couture, F., et al. (2007). Te impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharma-cokinetic profle of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ter 81:392-400.
54. Levesque, E., Turgeon, D., Carrier, J. S., Montminy, V., Beaulieu, M., Belanger, A. (2001). Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 40:3869-3881.
55. Li, Y. Q., Prentice, D. A., Howard, M. L., Mashford, M. L., Wilson, J. S., Desmond, P. V. (2000). Alcohol upregulates UDP-glucuronosyltransferase mRNA expression in rat liver and in primary rat hepatocyte culture. Life Sci 66:575-584.
56. Limenta, L. M., Jirasomprasert, T., Tankanitlert, J., Svasti, S., Wilairat, P., Chantharaksri, U., et al. (2008). UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol 65:908-916.
57. Macdonald, J. I., Herman, R. J., Verbeeck, R. K. (1990). Sex diference and the efects of smoking and oral contraceptive steroids on the kinetics of difunisal. Eur J Clin Pharmacol 38:175-179.
58. McCarver, D. G., Hines, R. N. (2002). Te ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ter 300:361-366.
59. Miners, J. O., Attwood, J., Birkett, D. J. (1983). Infuence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16:503-509.
60. Miners, J. O., Attwood, J., Birkett, D. J. (1984). Determinants of acetaminophen metabolism: efect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. Clin Pharmacol Ter 35:480-486.
61. Miners, J. O., Knights, K. M., Houston, J. B., Mackenzie, P. I. (2006). In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
62. Miners, J. O., Mackenzie, P. I. (1991). Drug glucuronidation in humans. Pharmacol Ter 51:347-369.
63. Miyagi, S. J., Collier, A. C. (2007). Pediatric development of glucuro-nidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos 35:1587-1592.
64. Mori, Y., Koide, A., Kobayashi, Y., Morimura, K., Kaneko, M., Fukushima, S. (2002). Efect of ethanol treatment on metabolic activation and detoxifcation of esophagus carcinogenic N-nitrosamines in rat liver. Mutagenesis 17:251-256.
65. Murry, D. J., Crom, W. R., Reddick, W. E., Bhargava, R., Evans, W. E. (1995). Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 23:1110-1116.
66. Nagar, S., Zalatoris, J. J., Blanchard, R. L. (2004). Human UGT1A6 pharmacogenetics: identifcation of a novel SNP, characterization of allele frequencies, and functional analysis of recom-binant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14:487-499.
67. Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., Yokoi, T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
68. Narayan, S. S., Hayton, W. L., Yost, G. S. (1991). Chronic ethanol consumption causes increased glucuronidation of morphine in rabbits. Xenobiotica 21:515-524.
69. Nishimura, M., Naito, S. (2006). Tissue-specifc mRNA expression profles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374.
70. Nozawa, M., Ohnuma, T., Matsubara, Y., Sakai, Y., Hatano, T., Hanzawa, R., et al. (2008). Te relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ter Drug Monit 30:35-40.
71. Ochs, H. R., Greenblatt, D. J., Knuchel, M. (1985). Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. Chest 87:223-226.
72. Ochs, H. R., Greenblatt, D. J., Otten, H. (1981). Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr 59:899-903.
73. Ohno, S., Nakajin, S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
74. Pacifci, G. M., Rane, A. (1982). Distribution of UDP- glucuronyltransferase in diferent human foetal tissues. Br J Clin Pharmacol 13:732-735.
75. Pacifci, G. M., Sawe, J., Kager, L., Rane, A. (1982). Morphine glucuro-nidation in human fetal and adult liver. Eur J Clin Pharmacol 22:553-558.
76. Parkinson, A., Mudra, D. R., Johnson, C., Dwyer, A., Carroll, K. M. (2004). Te efects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver micro-somes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209.
77. Peterkin, V. C., Bauman, J. N., Goosen, T. C., Menning, L., Man, M. Z., Paulauskis, J. D., et al. (2007). Limited infuence of UGT1A1*28 and no efect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver micro-somes. Br J Clin Pharmacol 64:458-468.
78. Pillot, T., Ouzzine, M., Fournel-Gigleux, S., Lafaurie, C., Radominska, A., Burchell, B., et al. (1993). Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4. J Biol Chem 268:25636-25642.
79. Ramchandani, R. P., Wang, Y., Booth, B. P., Ibrahim, A., Johnson, J. R., Rahman, A., et al. (2007). Te role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47:78-86.
80. Ramirez, J., Liu, W., Mirkov, S., Desai, A. A., Chen, P., Das, S., et al. (2007). Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos 35:2149-2153.
81. Rane, A., Sjoqvist, F., Orrenius, S. (1973). Drugs and fetal metabolism. Clin Pharmacol Ter 14:666-672.
82. Rollins, D. E., von Bahr, C., Glaumann, H., Moldeus, P., Rane, A. (1979). Acetaminophen: potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science 205:1414-1416.
83. Scavone, J. M., Greenblatt, D. J., LeDuc, B. W., Blyden, G. T., Luna, B. G., Harmatz, J. S. (1990). Diferential efect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. Pharmacology 40:77-84.
84. Strassburg, C. P., Strassburg, A., Kneip, S., Barut, A., Tukey, R. H., Rodeck, B., et al. (2002). Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259-265.
85. Tankanitlert, J., Morales, N. P., Howard, T. A., Fucharoen, P., Ware, R. E., Fucharoen, S., et al. (2007). Efects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE. Pharmacology 79:97-103.
86. Turgeon, D., Carrier, J. S., Levesque, E., Hum, D. W., Belanger, A. (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.
87. van Oijen, M. G., Barthelemy, C., Janssen, M. J., Joiris, E., Peters, W. H., Laheij, R. J., et al. (2009). Efect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. Pharmacology 83:237-242.
88. Villeneuve, J. P., Raymond, G., Bruneau, J., Colpron, L., Pomier-Layrargues, G. (1983). [Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects]. Gastroenterol Clin Biol 7:898-902.
89. Waxman, D. J., Holloway, M. G. (2009). Centennial perspective: sex diferences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol Epub May 29.
90. Wiener, D., Fang, J. L., Dossett, N., Lazarus, P. (2004). Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190-1196.
91. Yamanaka, H., Nakajima, M., Katoh, M., Hara, Y., Tachibana, O., Yamashita, J., et al. (2004). A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its efects on the transcriptional activity. Pharmacogenetics 14:329-332.
92. Yue, Q. Y., Svensson, J. O., Alm, C., Sjoqvist, F., Sawe, J. (1989). Interindividual and interethnic diferences in the demeth-ylation and glucuronidation of codeine. Br J Clin Pharmacol 28:629-637.
93. Yue, Q. Y., Tomson, T., Sawe, J. (1994). Carbamazepine and cigarette smoking induce diferentially the metabolism of codeine in man. Pharmacogenetics 4:193-198.
94. Zaya, M. J., Hines, R. N., Stevens, J. C. (2006). Epirubicin glucuro-nidation and UGT2B7 developmental expression. Drug Metab Dispos 34:2097-2101